louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00708188: Multidetector Raw CT as a Single Tool in the Setting of Ischemic Stroke
Official title: Evaluation of Multidetector Raw Computerized Tomography in the Etiological Analysis of Acute Ischemic Stroke: the "COCASE" Protocol.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ischemic Stroke
Keywords: Stroke, ischemic, etiology, TOAST, CT, multidetector
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2008-07-02
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a prospective study including acute ischemic stroke patients aged 18 to 90. Multidetector raw CT is performed in acute ischemic stroke patients. Heart, neck vessels and brain arteries are studied during the same acquisition. Results are compared with the standard methods including transesophageal echocardiography (TEE), Doppler ultrasound (DUS) and MR angiography (MRA) of neck vessels. The main criteria is the ability of CT to classify the stroke etiology correctly according to the TOAST classification in comparison with the standard methods.


Eligibility criteria: Inclusion Criteria:

* Acute (\< 1 week) ischemic stroke patient aged 18 to 90
* Informed consent obtained
* Presence of health insurance

Exclusion Criteria:

* Pregnancy or absence of efficient contraceptive method
* Allergy
* Allergy to contrast material
* Asthma
* Renal failure (blood creatinine \> 130 µmoles/l, creatinine clearance \< 80 ml/mn according to Cockroft method)
* Myeloma
* Hyperthyroidism (uncontrolled)
* Difficulties to synchronize CT to heart rhythm
* Contra-indication to TEE or MRI
* Absence or retirement of informed consent
* Absence of health insurance

Primary outcomes:
measure: Ability of CT to classify the stroke etiology correctly (TOAST classification) in comparison to reference methods (MRA, DUS, TEE)
timeFrame: classify the stroke etiology
Secondary outcomes:
measure: Ability of CT to detect the source of stroke in each etiological group. Reliability of CT in quantitative measures of artery stenosis, aortic atheroma, heart thrombus, heart tumors). Tolerance of CT
timeFrame: detect the source of stroke
Other outcomes:
Locations:
city: Bron
country: France
facility: Hôpital Cardiologique Louis Pradel
Study officials:
affiliation: Hospices Civils de Lyon
name: DOUEK Philippe, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Boussel L, Cakmak S, Wintermark M, Nighoghossian N, Loffroy R, Coulon P, Derex L, Cho TH, Douek PC. Ischemic stroke: etiologic work-up with multidetector CT of heart and extra- and intracranial arteries. Radiology. 2011 Jan;258(1):206-12. doi: 10.1148/radiol.10100804. Epub 2010 Nov 9.
Clinical trial NCT06720688: Association Between Ultrasound Morphology of Intestinal Endometriosis Nodules and Symptom Severity
Official title: Association Between Ultrasound Morphology of Intestinal Endometriosis Nodules and Symptom Severity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometriosis Rectum
Keywords: Endometriosis
Ultrasound
Gynaecology
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2024-12-06
Enrollment: 300
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with an ultrasound diagnosis of deep bowel endometriosis undergoing surgery and patients who are not candidates for surgery

Brief summary: Association between the ultrasound appearance of deep bowel endometriosis and the frequency of pain

Detailed description: In order to improve the diagnostic power of the ultrasound method, it is important to evaluate the association between the ultrasound appearance of the nodule of intestinal deep endometriosis and the frequency of pain, thus assessing the prevalence of moderate or severe clinical symptoms, in patients with newly diagnosed intestinal deep endometriosis, according to the ultrasound morphology of the posterior deep endometriosis nodule proposed in the International Deep Endometriosis Analysis Group (IDEA) Consesus.

Eligibility criteria: Inclusion Criteria:

* Patients aged ≥18 years;
* Presence of posterior rectus intestinal deep endometriosis confirmed on TV ultrasound between 01/01/2018 and 30/06/2023;
* Informed consent obtained

Exclusion Criteria:

* Virgo patients;
* Patients reporting intolerance to transvaginal ultrasound;
* Current or history of gynaecological oncology;
* Previous surgery of the sigma and rectum

Primary outcomes:
measure: Prevalence of moderate or severe clinical symptoms
timeFrame: At diagnosis or in the previous 6 months
Secondary outcomes:
measure: Ultrasound morphologies of the intestinal endometriosis nodule and the frequency of associated lesions
timeFrame: At diagnosis or in the previous 6 months
measure: Association between ultrasound morphology and specific clinical symptoms
timeFrame: At diagnosis or in the previous 6 months
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study officials:
affiliation: IRCCS Azienda Ospedaliero-Universitaria di Bologna
name: Diego Raimondo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06842888: Comparing Mirror Therapy Rehabilitation Device to Conventional Mirror Therapy
Official title: Comparing Mirror Therapy Rehabilitation Device to Conventional Mirror Therapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke
Pain
Impaired Motor Function
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2025-02-24
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Inpatients undergoing inpatient rehabilitation in the IRU (inpatient rehabilitation unit) at the Yale New Haven Hospital Rehabilitation and Wellness Center
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled trial which will compare conventional mirror therapy with mirror therapy using the Miraπ device which physically moves a patient's affected limb.

This study will use two parallel groups: (1) receiving conventional mirror therapy as a part of the standard of care as conducted by the participant's clinical care team and (2) receiving mirror therapy with the Miraπ device as conducted by study personnel with the oversight of the participant's clinical care team.


Eligibility criteria: Inclusion Criteria:

* Participants currently accepted and cleared for rehabilitation in the inpatient rehabilitation unit by the rehabilitation medical director.
* Participants with paralysis or motor function problems of only one hand.
* Participants need mirror therapy because of their health condition.
* Participants' rehabilitation physician determined that mirror therapy would be appropriate for standard of care.
* Participants are able to memorize easy tasks, and able to follow instructions e.g., moving the healthy fingers.

Exclusion Criteria:

* Participants who are not cleared physically or medically to participate in standard acute inpatient rehabilitation therapies by the rehabilitation medical director
* Participants who are not able to memorize easy tasks, e.g., moving the healthy fingers.
* Participants with spasticity of the affected hand (as assed by the occupational therapist)
* Minors
* Vulnerable populations

Primary outcomes:
measure: Change in Jebsen-Taylor Hand Function Test score
timeFrame: At baseline and at discharge (approximately 2-3 weeks after baseline)
measure: McGill Pain Questionnaire (MPQ)
timeFrame: At baseline and at discharge (approximately 2-3 weeks after baseline)
measure: Change in Visual Analog Scale (VAS) to assess Pain
timeFrame: At baseline and at discharge (approximately 2-3 weeks after baseline)
Secondary outcomes:
Other outcomes:
Locations:
city: Milford
country: United States
facility: Rehabilitation and Wellness Center at the Milford Campus of Bridgeport Hospital
state: Connecticut
Study officials:
affiliation: Yale University
name: Necolle Morgado-Vega
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00725088: Study of Rehabilitation Therapy on Patients After Acute Myocardial Infarction
Official title: Study of Rehabilitation Therapy on Patients After Acute Myocardial Infarction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Myocardial Infarction
Keywords: ST-Elevated Myocardial Infarction
Exercise Training
Rehabilitation
Lead sponsor: Ministry of Science and Technology of the People´s Republic of China
Sponsor class: OTHER_GOV
First posted: 2008-07-30
Enrollment: 300
Sex: ALL
Minimum age (years): 35
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether exercise rehabilitation can reduce mortality, reinfarction or heart failure of patients after acute myocardial infarction.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of ST-elevated myocardial infarction
* Heart function class I-II(killip classification)
* Agree to take cardiopulmonary exercise testing before discharge
* Signature of the informed consent document

Exclusion Criteria:

* History of myocardial infarction
* Acute myocardial infarction with severe complications(such as pulmonary edema, severe cardiac arrhythmia or cardiogenic shock)
* Atrial fibrillation
* Other severe diseases, such as HIV infection, malignant tumor or chronic diseases of liver, kidney or pulmonary
* Not be capable of exercise training

Primary outcomes:
measure: Cardiac mortality
timeFrame: one year
Secondary outcomes:
measure: Non-fatal reinfarction, revascularization(PCI/CABG), ischemic stroke, unstable angina pectoris needs for hospitalization, severe heart failure needs for hospitalization
timeFrame: one year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: Wei Gao, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05095688: Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Official title: Relationship Between Adipose Tissue Distribution and Arterial Stiffness in Heart Failure With Preserved Ejection Fraction(HFpEF)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Failure With Preserved Ejection Fraction
Arterial Stiffness
Lipid Disorder
Lead sponsor: Chongqing Medical University
Sponsor class: OTHER
First posted: 2021-10-27
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Heart failure patients with preserved ejection fraction (HFpEF)

Brief summary: Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. Studies have found that hypertension and obesity are respectively associated with increased arterial stiffness. However, there is still no research investigating the the relationship between lipids distribution and arterial stiffness in HFpEF patients.

Detailed description: Before the 21st century, Heart failure with preserved ejection fraction (HFpEF) was considered as a disease with simple diastolic dysfunction, but after the 21st century, HFpEF was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. Other studies have found that hypertension and obesity are respectively associated with increased arterial stiffness. However, there is still no research investigating the the relationship between lipids distribution and arterial stiffness in HFpEF patients.

Eligibility criteria: Inclusion Criteria:

1. Adult aged \>=18years old;
2. Diagnosed with HFpEF.

Diagnostic criteria including:

1. left ventricular ejection fraction ≥50%；
2. with the symptoms and/or signs of heart failure；
3. BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL；
4. at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction

Exclusion Criteria:

1. LVEF less than 45% at any time;
2. Severe liver failure; 3/Other causes of shortness of breath, such as severe pulmonary disease or severe chronic obstructive pulmonary disease;

4.Primary pulmonary hypertension; 5.Severe valvular disease of the left heart; 6.Chronically bedridden or incapacitated; 7.Age \<18 years old.

Primary outcomes:
measure: Arterial stiffness
timeFrame: 1 day after admission
measure: adipose tissue distribution
timeFrame: 1 day after admission
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
Study officials:
References:
Clinical trial NCT02272088: Effect of Different Intensities of Exercise on Daily Energy Expenditure With Physical Activity in Overweight Boys
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: physical activity
energy expenditure
compensatory mechanisms
adolescent
Lead sponsor: Rio de Janeiro State University
Sponsor class: OTHER
First posted: 2014-10-22
Enrollment: 24
Sex: MALE
Minimum age (years): 11
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The main purpose of this study is evaluate the effect of different intensities of exercise (moderate vs. intense) on the daily energy expenditure in overweight adolescents.

Detailed description: The specific objectives are:

1. Assess and quantify the existence of compensatory effect of exercise on subsequent physical activity.
2. Compare the amount of daily physical activity in adolescents subjected to different protocols of training intensity.

Eligibility criteria: Inclusion Criteria:

overweight 6th and 7th grades students consent form signed by parents / tutors

Exclusion Criteria:

diabetes mellitus hypertension or reported cardiovascular disease

Primary outcomes:
measure: energy expenditure
timeFrame: one week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Paravidino VB, Mediano MFF, Sichieri R. Does a single bout of exercise influence subsequent physical activity and sedentary time in overweight boys? Physiol Behav. 2017 May 1;173:231-235. doi: 10.1016/j.physbeh.2017.02.016. Epub 2017 Feb 20.
citation: Paravidino VB, Mediano MF, Hoffman DJ, Sichieri R. Effect of Exercise Intensity on Spontaneous Physical Activity Energy Expenditure in Overweight Boys: A Crossover Study. PLoS One. 2016 Jan 15;11(1):e0147141. doi: 10.1371/journal.pone.0147141. eCollection 2016.
Clinical trial NCT05089188: PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation
Official title: PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Melanoma
Keywords: Immunohistochemistry
Histopathology
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2021-10-22
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All cases with histopathological diagnosis of "ambiguous melanocytic proliferation" or "atypical melanocytic proliferation" made between January 2016 and December 2020.

Brief summary: Skin melanoma is a common form of skin cancer. Its diagnosis is usually clinically suspected and then affirmed by histopathological examination.

In some cases, the histopathological analysis of these lesions is equivocal, and the malignant or benign nature of the proliferation is difficult to determine with certainty. In these cases, the use of expensive ancillary tests, which are hardly accessible and take a long time to set up (FISH - CGH-array), is usually required.

Anti-PRAME immunostaining, an inexpensive and readily available technic, has recently been described as highly sensitive and specific for diagnosing malignant melanocytic proliferations. Knowledge on its utility for evaluating ambiguous melanocytic neoplasms remains limited.

Our study aims to improve the current body of knowledge on the utility of PRAME immunohistochemistry for evaluating challenging samples of melanocytic proliferation. The secondary objective is to determine the PRAME immunoreactivity profile for each histological subtype of melanocytic proliferations (spitzoid tumors, cellular blue nevi, dysplastic nevi ...)


Eligibility criteria: Inclusion Criteria:

* Adult patient at the time of diagnosis (\> = 18 years).
* histopathological diagnosis of "ambiguous melanocytic proliferation" or "atypical melanocytic proliferation" made between January 2016 and December 2020.
* Histological slides archived in the "CRB" biobank available
* Formalin-fixed paraffin-embedded tissue block archived in the "CRB" biobank available
* Informed patient

Exclusion Criteria:

* Patient who has expressed opposition to participating in the study.

Primary outcomes:
measure: Immunomarkers
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Les Hôpitaux Universitaires de Strasbourg
Study officials:
References:
Clinical trial NCT05688488: Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords
Official title: Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Glottic Web of Larynx
Laryngeal Stenosis
Glottic Carcinoma
Laryngeal Leucoplakia
Laryngeal Polyp
Laryngeal Papilloma
Keywords: Curcumin
Lead sponsor: Eye & ENT Hospital of Fudan University
Sponsor class: OTHER
First posted: 2023-01-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To provide a novel therapy idea and method to solve the clinical problem of postoperative adhesion of bilateral vocal cords, patients enrolled in this study will be applied with curcumin on both wound sites of bilateral vocal cords after the surgery on the bilateral vocal cord endoscopically.


Eligibility criteria: Inclusion Criteria:

1. Patients with bilateral vocal cord diseases who are going to undergo resection of bilateral vocal cord lesions endoscopically.
2. Patients with bilateral vocal cord adhesion who are going to undergo incision of bilateral vocal cord adhesion endoscopically.

Exclusion Criteria:

1. Patients with other laryngeal diseases.
2. Patients with cardiac and pulmonary insufficiency.
3. Patients unable to cooperate with the follow-up on time after surgery.
4. Patients who refuse to sign the informed consent after notification.
5. Patients who have a severe allergic disease or allergic history to a variety of drugs.
6. Other circumstances that are not appropriate to be included in the clinical trial.

Primary outcomes:
measure: Number of participants with laryngeal web formation as assessed by videolaryngoscope
timeFrame: 1 year postsurgery
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Eye & ENT Hospital of Fudan University
state: Shanghai
Study officials:
References:
Clinical trial NCT04892888: Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms
Official title: Special Use Results Survey: Spikevax Intramuscular Injection (Previously COVID-19 Vaccine Moderna Intramuscular Injection) for Subjects With Underlying Disease Considered to be at High Risk for Severe Illness, Acute Phase Safety Surveillance (COVID-19)
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Coronavirus Disease (COVID-19)
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2021-05-19
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The population of this survey are vaccinees who meet the inclusion/exclusion criteria.

Brief summary: This study is a survey of the Moderna COVID-19 vaccine in Japanese people at high risk of developing severe COVID-19 symptoms. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects of the Moderna COVID-19 vaccine in this group. This will be from the first vaccination to 28 days after the second vaccination.

The number of visits to the clinic will depend on the clinic's standard practice.


Eligibility criteria: Inclusion Criteria:

1. The participant is capable of understanding the contents of the investigation, recording his/her own symptoms in the health observation diary, and has obtained written consent to participate in the investigation from the vaccinee himself/herself (If minor, parent or legal guardian).
2. The participant has an underlying disease at the time of this drug vaccination that is considered to pose a high risk of aggravation of COVID-19.

Exclusion Criteria:

1. The subject has any contraindication to this drug.

Primary outcomes:
measure: Percentage of Participants with at least One Adverse Events (AEs)
timeFrame: 56 days
measure: Percentage of Participants with Specified AEs (Local Reactions) at the Vaccination Site
timeFrame: 56 days
measure: Percentage of Participants with Specified AEs (Systemic Events)
timeFrame: 56 days
Secondary outcomes:
measure: Number of Participants who Take COVID-19 Pathogen (SARS-COV-2) Test during the Study
timeFrame: 56 days
measure: Number of Participants who Developed COVID-19 during the Study
timeFrame: 56 days
measure: Number of Participants Who Have Sever COVID-19 Infection during the Study Evaluated by Investigator
timeFrame: 56 days
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Takeda Selected Site
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References: